Looks like you’re on the UK site. Choose another location to see content specific to your location
Bristol-Myers Squibb and CytomX agree immuno-oncology alliance
Bristol-Myers Squibb has agreed to partner with CytomX Therapeutics on the development of a number of novel therapies against multiple immuno-oncology targets.
The worldwide research collaboration and license agreement will involve the discovery, development and commercialisation of a number of agents using CytomX's proprietary Probody platform.
Probodies are monoclonal antibodies that can be selectively activated within the cancer microenvironment, focusing the activity of therapeutic antibodies on tumours, while leaving the healthy tissue unaffected.
Bristol-Myers Squibb will gain exclusive worldwide rights to develop and commercialise Probodies for up to four oncology targets, including CTLA-4, a clinically validated immune inhibitory checkpoint receptor.
Francis Cuss, executive vice-president and chief scientific officer at Bristol-Myers Squibb, said: "The Probody platform has the potential to broaden discovery of innovative therapies and the collaboration with CytomX reflects our continued leadership in immuno-oncology."
This comes as the company prepares to present data from its promising immuno-oncology portfolio at the forthcoming American Society of Clinical Oncology annual meeting, which takes place in Chicago from May 30th to June 3rd 2014.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard